A Food and Drug Administration advisory panel on Tuesday overwhelmingly recommended against using the drug ecstasy combined with psychotherapy to treat PTSD, possibly derailing what would be the first psychedelic drug approval in the U.S.
Why it matters: While there's a growing effort to use hallucinogenic substances as behavioral health treatments, regulators are grappling with how to judge their safety and effectiveness, and there's a high risk for misuse.
